Evaluation of CG-100 Intraluminal Bypass Device

July 1, 2026 updated by: Colospan Ltd.
Evaluation of CG-100 Intraluminal Bypass device

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

7

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Rehovot, Israel
        • Soroka Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria (pre-operative):

  1. Willing to comply with protocol-specified follow-up evaluations
  2. 22-75 (inclusive) years of age at screening
  3. Diagnosed with colorectal cancer
  4. Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CG-100 Intraluminal Bypass Device
Subjects will be treated with CG-100 Intraluminal Bypass Device
Device: CG-100 Intraluminal Bypass Device
Subjects will be treated with the CG-100 Intraluminal Bypass Device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of the CG-100 Intraluminal Bypass Device
Time Frame: 10 days
Assessment of Serious Adverse Events
10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of the CG-100 Intraluminal Bypass Device
Time Frame: 4 weeks
Assessment of Serious Adverse Events
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Colospan Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 15, 2023

Primary Completion (Actual)

April 15, 2024

Study Completion (Actual)

April 15, 2024

Study Registration Dates

First Submitted

November 8, 2022

First Submitted That Met QC Criteria

November 27, 2022

First Posted (Actual)

December 1, 2022

Study Record Updates

Last Update Posted (Actual)

July 2, 2026

Last Update Submitted That Met QC Criteria

July 1, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CLD-113

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe